New AdventHealth Study Examines the Role of the Gut Microbiome in Efficacy of Immunotherapy Treatment for Gynecological Cancers

Lab with petri dish

Numerous studies in recent years have identified disturbance of gut microbial metabolism as a potential cause of chronic disease, leading researchers to begin studying the specific impact of the gut microbiome on cancers, including melanoma and colorectal cancers. Another study published last year in Communications Biology found that gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation.

Inspired by this research, along with her own passion for metabolic and lifestyle medicine, AdventHealth Cancer Institute gynecologic oncologist Nathalie D. McKenzie, MD, recently launched a pilot feasibility study to begin exploring the interplay of the gut microbiome on the efficacy of immunotherapy treatment for gynecological cancers.

Nathalie McKenzie, MD
Nathalie D. McKenzie, MD, is a board-certified gynecologic oncologist and cancer survivor who serves as program director of the gynecologic oncology fellowship at AdventHealth Cancer Institute.

“This initial study is observational,” explains McKenzie, noting that the collection of microorganisms in the gut – including bacteria, archaea, viruses, and fungi – and their overall genetic information play an essential role in the health of its host, both in humans as well as animals.

The study is currently enrolling up to 30 participants with advanced or recurrent gynecological cancer who plan to receive immunotherapy treatment with a checkpoint inhibitor at AdventHealth.

“The gut microbiome’s key functions are all related to metabolism, immune system education and regulation, and protection against pathogen invasion,” McKenzie added. “This study will help us understand not only how the gut microbiome changes within the individual as they undergo immunotherapy, but also how it differs among patients throughout the course of their treatment.”

McKenzie, who is the principal investigator on this AdventHealth study, and her team will collect fecal, blood, saliva and vaginal samples three times: 1) prior to first treatment, 2) after four doses of immunotherapy, and 3) at the completion of immunotherapy.

These four biomarker samples will undergo metatranscriptomic analysis. Also known as RNA-seq, this method of sample analysis will only sequence RNA molecules while DNA is degraded to allow for bacterial community analysis. In addition, study participants will complete a National Health and Nutrition Examination Survey (NHANES) Food Frequency Questionnaire prior to their first treatments.

The findings of this pilot feasibility study will help design a larger study to further examine the role of the gut microbiome in anti-tumor immunity and its effect on immune checkpoint inhibitor therapy for advanced or recurrent gynecological cancers.

“This study is just the first step,” shares McKenzie. “It will help us better understand the specific metabolites and bacteria that could impact treatment.”

This study is part of a collaboration with Viome Life Sciences, a systems biology and artificial intelligence company working to develop next generation of diagnostics and therapeutics to detect disease earlier and improve treatment.

AdventHealth collects the data and Viome analyzes the clinical specimens.

“From the specimens, we can generate vast amounts of molecular data relevant to chronic diseases and cancers,” said Momo Vuyisich, PhD, Viome Life Sciences chief science officer. “Machine learning and artificial intelligence then makes sense of the data and translates the findings into clinically useful diagnostics and therapeutics.”

In Dr. McKenzie’s published paper in Critical Reviews in Oncology/Hematology, she discusses the data surrounding the interplay between lifestyle cancer and the gut microbiome.
In Dr. McKenzie’s published paper in Critical Reviews in Oncology/Hematology, she discusses the data surrounding the interplay between lifestyle cancer and the gut microbiome.

Ultimately, McKenzie hopes to conduct additional studies to determine if specific interventions can be applied to influence the gut microbiome and create a better response to immunotherapy for gynecologic cancer patients.

“Using the principles of precision medicine, I want to explore if we can enhance efficacy and outcomes for our patients through lifestyle changes, nutraceuticals, oncology-specific microbial therapeutics or some combination of these approaches,” said McKenzie. “This is an exciting area of research, and I think we have multiple opportunities to improve and optimize cancer care — through prevention, pre-therapy preparation, therapy support and post-therapy protocols — to help women recover better, faster and with greater quality of life.”

Physicians with questions about this study or a specific gynecologic oncology case can contact AdventHealth GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy

Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...

Read Article about "New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy "
News
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease

Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...

Read Article about "AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease"
News
AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes

Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...

Read Article about "AdventHealth’s Karen D. Corbin, PhD, RD, Contributed to New American Diabetes Association Consensus Statement on Liver Disease in Diabetes "
News
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training

With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...

Read Article about "AdventHealth Research Institute and NESTRE Health and Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training "
View More Articles